SUIC Worldwide Holdings Ltd. (OTC Markets: SUIC) and VisionRenu Biomedical Technology Co., Ltd. have announced the signing of a Strategic Memorandum of Understanding (MOU) to collaborate on AI-powered biotechnology, precision medicine, and U.S. capital market initiatives. The agreement establishes a framework for combining their strengths in medical technology innovation, commercialization, and international business development, with the goal of accelerating VisionRenu's global expansion while creating long-term value through strategic financing and potential U.S. capital market opportunities.
The collaboration is particularly significant as AI continues to reshape the biotechnology industry. AI enables faster discovery of disease-related genes, improves CRISPR gene-editing precision, optimizes DNA and protein design, and shortens development cycles for next-generation therapeutics. Combined with automated DNA synthesis and robotic laboratories, AI is transforming biological research through the Design-Build-Test-Learn (DBTL) platform. Industry analysts expect AI-enabled biotechnology to become one of the world's largest innovation markets, creating multi-trillion-dollar opportunities across healthcare, drug discovery, synthetic biology, advanced manufacturing, and sustainable materials.
Under the MOU, SUIC and VisionRenu will leverage AI, precision medicine, gene technologies, and international capital market resources to accelerate innovation. SUIC's strategic collaboration and proposed merger with VisionRenu, together with partnerships involving AI biotechnology startups supported by Taiwan's Ministry of Health and Welfare (MOHW), position the company to expand into this rapidly growing sector. Both companies view the agreement as the first step toward building a long-term strategic partnership focused on innovation and sustainable growth.
VisionRenu is a Taiwan-based medical technology company specializing in brain health and ophthalmic medical devices. Its flagship product, the MagRenu® Transcranial Magnetic Stimulation (TMS) System, is approved by Taiwan's TFDA for the treatment of depression. The company is also developing proprietary ophthalmic laser technologies. For more information, visit https://www.vision-renu.com/.
SUIC Worldwide Holdings Ltd. is a technology-enabled investment and business acceleration company focused on acquiring and developing innovative businesses with high-growth potential. Through strategic investments, mergers and acquisitions, and access to international capital markets, SUIC supports portfolio companies in expanding globally. For more information, visit https://sinounitedco.com/.
